Overview

Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder

Status:
Withdrawn
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This primary purpose of this study is to assess the efficacy and safety of Effexor XR in preventing recurrence in Chinese patients with recurrent major depressive disorder (MDD) following a 1-year maintenance treatment after an 8-week acute treatment and a 6-month continuation treatment phases. The study will also collect data on the prevalence and pattern of co-morbid anxiety and somatic symptoms and their impact on the recurrence of depression.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Venlafaxine Hydrochloride